TrialAnnals of the rheumatic diseases2018

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Sophie Glatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.